Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancer

Abstract Objective To explore the survival effect of thoracic gross tumor volume (GTV) in three‐dimensional (3D) radiotherapy for stage IV non‐small cell lung cancer (NSCLC). Methods The data cases were obtained from a single‐center retrospective analysis. From May. From 2008 to August 2018, 377 tre...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaxia Chen, Wei Zhang, Lan Luo, Shimei Fu, Dongdong Cao, Shengfa Su, Qingsong Li, Wengang Yang, Yichao Geng, Bing Lu, Weiwei Ouyang
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.70221
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1825206479639019520
author Xiaxia Chen
Wei Zhang
Lan Luo
Shimei Fu
Dongdong Cao
Shengfa Su
Qingsong Li
Wengang Yang
Yichao Geng
Bing Lu
Weiwei Ouyang
author_facet Xiaxia Chen
Wei Zhang
Lan Luo
Shimei Fu
Dongdong Cao
Shengfa Su
Qingsong Li
Wengang Yang
Yichao Geng
Bing Lu
Weiwei Ouyang
author_sort Xiaxia Chen
collection DOAJ
description Abstract Objective To explore the survival effect of thoracic gross tumor volume (GTV) in three‐dimensional (3D) radiotherapy for stage IV non‐small cell lung cancer (NSCLC). Methods The data cases were obtained from a single‐center retrospective analysis. From May. From 2008 to August 2018, 377 treatment criteria were enrolled. GTV was defined as the volume of the primary lesion and the hilus as well as the mediastinal metastatic lymph node. Chemotherapy was a platinum‐based combined regimen of two drugs. The number of median chemotherapy cycles was 4 (2–6), and the cut‐off value of the planning target volume (PTV) dose of the primary tumor was 63 Gy (30–76.5 Gy). The cut‐off value of GTV volume was 150 cm3 (5.83–3535.20 cm3). Results The survival rate of patients with GTV <150 cm3 is better than patients with GTV ≥150 cm3. Multivariate Cox regression analyses suggested that peripheral lung cancer, radiation dose ≥63 Gy, GTV <150 cm3, 4–6 cycles of chemotherapy, and CR + PR are good prognostic factors for patients with stage IV non‐small cell lung cancer. The survival rate of patients with GTV <150 cm3 was longer than patients with ≥150 cm3 when they underwent 2 to 3 cycles of chemotherapy concurrent 3D radiotherapy (p < 0.05). When performing 4 to 6 cycles of chemotherapy concurrent 3D radiotherapy, there was no significant difference between <150 cm3 and ≥150 cm3. Conclusions The volume of stage IV NSCLC primary tumor can affect the survival of patients. Appropriate treatment methods can be opted by considering the volume of tumors to extend patients' lifetime to the utmost.
format Article
id doaj-art-623b953f37c446efbc4019d95730ef4a
institution Kabale University
issn 2045-7634
language English
publishDate 2024-09-01
publisher Wiley
record_format Article
series Cancer Medicine
spelling doaj-art-623b953f37c446efbc4019d95730ef4a2025-02-07T09:08:08ZengWileyCancer Medicine2045-76342024-09-011317n/an/a10.1002/cam4.70221Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancerXiaxia Chen0Wei Zhang1Lan Luo2Shimei Fu3Dongdong Cao4Shengfa Su5Qingsong Li6Wengang Yang7Yichao Geng8Bing Lu9Weiwei Ouyang10Department of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaDepartment of Oncology Guizhou Hospital of the First Affiliated Hospital of Sun Yat‐sen University Guiyang ChinaDepartment of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaDepartment of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaDepartment of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaDepartment of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaDepartment of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaDepartment of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaDepartment of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaDepartment of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaDepartment of Oncology The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University Guiyang Guizhou ChinaAbstract Objective To explore the survival effect of thoracic gross tumor volume (GTV) in three‐dimensional (3D) radiotherapy for stage IV non‐small cell lung cancer (NSCLC). Methods The data cases were obtained from a single‐center retrospective analysis. From May. From 2008 to August 2018, 377 treatment criteria were enrolled. GTV was defined as the volume of the primary lesion and the hilus as well as the mediastinal metastatic lymph node. Chemotherapy was a platinum‐based combined regimen of two drugs. The number of median chemotherapy cycles was 4 (2–6), and the cut‐off value of the planning target volume (PTV) dose of the primary tumor was 63 Gy (30–76.5 Gy). The cut‐off value of GTV volume was 150 cm3 (5.83–3535.20 cm3). Results The survival rate of patients with GTV <150 cm3 is better than patients with GTV ≥150 cm3. Multivariate Cox regression analyses suggested that peripheral lung cancer, radiation dose ≥63 Gy, GTV <150 cm3, 4–6 cycles of chemotherapy, and CR + PR are good prognostic factors for patients with stage IV non‐small cell lung cancer. The survival rate of patients with GTV <150 cm3 was longer than patients with ≥150 cm3 when they underwent 2 to 3 cycles of chemotherapy concurrent 3D radiotherapy (p < 0.05). When performing 4 to 6 cycles of chemotherapy concurrent 3D radiotherapy, there was no significant difference between <150 cm3 and ≥150 cm3. Conclusions The volume of stage IV NSCLC primary tumor can affect the survival of patients. Appropriate treatment methods can be opted by considering the volume of tumors to extend patients' lifetime to the utmost.https://doi.org/10.1002/cam4.70221concurrent chemoradiotherapynon‐small cell lung cancerstage IVsurvivalthree‐dimensional radiotherapy
spellingShingle Xiaxia Chen
Wei Zhang
Lan Luo
Shimei Fu
Dongdong Cao
Shengfa Su
Qingsong Li
Wengang Yang
Yichao Geng
Bing Lu
Weiwei Ouyang
Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancer
Cancer Medicine
concurrent chemoradiotherapy
non‐small cell lung cancer
stage IV
survival
three‐dimensional radiotherapy
title Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancer
title_full Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancer
title_fullStr Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancer
title_full_unstemmed Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancer
title_short Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancer
title_sort effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage iv non small cell lung cancer
topic concurrent chemoradiotherapy
non‐small cell lung cancer
stage IV
survival
three‐dimensional radiotherapy
url https://doi.org/10.1002/cam4.70221
work_keys_str_mv AT xiaxiachen effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT weizhang effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT lanluo effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT shimeifu effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT dongdongcao effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT shengfasu effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT qingsongli effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT wengangyang effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT yichaogeng effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT binglu effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer
AT weiweiouyang effectofprimarytumorvolumeonsurvivalofconcurrentchemoradiotherapyinstageivnonsmallcelllungcancer